The $70$ Million Test: Deconstructing Connecticut’s Corporate Gross Income Threshold for Refundable R&D Tax Credits (Conn. Gen. Stat. § 12-217ee)

The Corporate Gross Income Test is the key financial metric determining a company’s eligibility for cash monetization of Connecticut R&D tax credits. Companies must demonstrate prior-year gross income below the $70 million threshold to qualify as a Qualified Small Business (QSB) for the credit exchange program.

This critical test provides vital liquidity to small, innovation-focused C-corporations that generate substantial R&D credits but lack sufficient Connecticut tax liability to utilize them. Successful navigation of this test allows a QSB to exchange unused current-year credits for a refundable sum, though strict anti-abuse and annual caps apply.

II. Statutory Framework of the Connecticut R&D Credit Program

The Connecticut General Statutes (CGS), Chapter 208, provides the framework for two primary R&D tax credits that are available exclusively to C-corporations filing Form CT-1120.1 These credits are designed to incentivize research and experimental activities conducted within the state.

A. Distinguishing R&D Credit Types Subject to Exchange

The QSB refund mechanism applies to unused credits generated under both the incremental and non-incremental methodologies, provided the taxpayer otherwise meets all eligibility criteria.

The Research and Experimental Expenditures (RC Credit), detailed in CGS § 12-217j, is an incremental credit. It equals 20% of the amount by which qualified research and experimental expenditures incurred in Connecticut during the current tax year exceed the amount spent during the preceding year.1 This credit has a useful life, carrying forward for up to 15 years if unused.1

The Research and Development Expenditures (RDC Credit), detailed in CGS § 12-217n, is a non-incremental credit. Its calculation is based on the total current year R&D expenses. For QSBs, the law generally allows a favorable 6% rate applied to all R&D costs.2 For larger corporations, the rate is tiered, ranging from 1% to 6% based on the total expenditure amount.2 Unused RDC credits have an indefinite carryforward period.1

Both credits are initially used to offset the Corporation Business Tax (CBT), typically limited to 70% of the tax due.2 It is only when the QSB has no remaining tax liability that the exchange mechanism becomes relevant.5

B. The Qualified Small Business (QSB) Definition: A Two-Tiered System

A critical nuance in Connecticut R&D tax policy involves the presence of two distinct gross income thresholds used to define a Qualified Small Business. Taxpayers must understand which threshold applies to the specific benefit being claimed.

This structure enforces two separate financial qualification bars. The higher $\$100$ million limit grants access to a more generous credit calculation methodology (the 6% rate).7 This benefit is primarily recognized if the company has sufficient tax liability or chooses to defer the credits.

Conversely, the lower $\$70$ million limit, stipulated in CGS § 12-217ee, applies strictly to the cash exchange program.3 This distinction reflects the legislature’s intent to set a stricter financial requirement for programs that involve a direct state outlay of cash (a non-tax expenditure). A company with prior-year gross income between $\$70$ million and $\$100$ million may qualify as a QSB for credit calculation but is explicitly excluded from receiving a cash refund for any unused credits.

III. Statutory Qualification: The $70$ Million QSB Gross Income Test

The $\$70$ million test is established by CGS § 12-217ee and is enforced by the Department of Revenue Services (DRS) as a gatekeeper for the cash refund program. Qualification requires meeting both a quantitative financial measure and a qualitative anti-abuse standard.

A. Core Requirement: Defining Prior Income Year Gross Income

For a company to qualify as a QSB for the credit exchange, its gross income for the previous income year must not exceed $\$70$ million.9

1. Definition of Gross Income

Connecticut law dictates the definition of gross income for CBT purposes. CGS § 12-213 defines “Gross income” as “gross income, as defined in the Internal Revenue Code, and, in addition, means any interest or exempt interest dividends”.10 This standard is tied directly to federal tax accounting principles. For C-corporations, the relevant figure generally corresponds to the gross receipts reported on the Federal Form 1120, Line 11.11 When applying for the exchange on Form CT-1120 XCH, the total gross income from all sources must be reported.12 If the application is made for a short period, the gross income for the previous income year must be appropriately annualized.12

2. The Qualified Small Business Exemption Requirement

The ability to exchange the credit for a refund is only available if the QSB cannot use the credit due to having no Corporation Business Tax liability.5 This lack of liability must be demonstrated by either having a zero or negative apportioned net income (regardless of the minimum capital base tax due) or having a capital base tax liability equal to the $\$250$ minimum.3 This ensures the cash refund mechanism primarily benefits pre-profit or minimally profitable businesses that require immediate working capital.

B. The “Related Person” Anti-Abuse Provision

Beyond the numerical $\$70$ million threshold, the QSB definition includes a crucial anti-abuse provision that requires a qualitative assessment of the company’s revenue streams. Under CGS § 12-217ee(e)(2), a company is disqualified if it has “not, in the determination of the commissioner, met the gross income test through transactions with a related person, as defined in section 12-217w”.3

1. Definition of “Related Person”

The definition of “related person” found in CGS § 12-217w centers on control and affiliated groups.14 Control is generally defined as ownership, directly or indirectly, of stock possessing 50% or more of the total combined voting power of all classes of stock.14 This includes corporations, partnerships, associations, or trusts controlled by the applicant company; entities in control of the applicant company; or any member of the same controlled group.14

2. Purpose and Implication of the Anti-Abuse Rule

The explicit inclusion of the related person test means that simply having a standalone gross income under $\$70$ million is not sufficient if that income is artificially derived from affiliated transactions. This requirement elevates the QSB test from a simple mathematical calculation to a substantive analysis subject to the judgment of the DRS Commissioner.9

This rule prevents large corporate groups from segmenting R&D-intensive units, particularly those that are revenue-generating but pre-profit, into separate corporate entities solely to claim the state cash refund. Since the purpose of the exchange program is to support small businesses that genuinely lack external funding, allowing large organizations to receive subsidized R&D funding via cash refunds would undermine the policy’s intent. Taxpayers within combined unitary reporting groups or complex sister-subsidiary arrangements must be prepared to demonstrate that their revenue streams are economically justified and independent of manipulation designed to meet the $\$70$ million criterion.12

IV. Mechanics of the R&D Credit Exchange

For eligible QSBs, the exchange process provides immediate liquidity, subject to a statutory rate reduction and an absolute annual ceiling.

A. The Standard Exchange Rate and Annual Monetary Cap

A qualified small business that elects the exchange must surrender a portion of the credit’s value to receive immediate cash.3

• Standard Exchange Rate: The unused credit is exchanged for a credit refund equal to 65% of the credit’s value.1 The company forgoes 35% of the credit value in exchange for monetization.
• Annual Cap: The maximum cash refund a QSB may receive in any one income year is strictly capped at $1,500,000.1

The existence of the $\$1.5$ million cap imposes a strategic constraint on highly R&D-intensive firms. Under the 65% standard exchange rate, a QSB maximizes the cash benefit by generating a credit value of approximately $\$2,307,692$ $(\$1,500,000 / 0.65)$. Any credit generated above this calculated figure must either be carried forward (at 100% of its value) or forfeited, compelling detailed tax modeling to optimize the utilization of annual R&D expenditures.

B. Enhanced Biotech Exchange Rate for Qualifying Companies

Recognizing the economic development importance of the biotechnology sector, Connecticut enacted an enhancement to the exchange rate for qualifying biotech companies.

• Increased Rate: For income years beginning on or after January 1, 2025, qualifying small biotech C-corporations that meet the $\$70$ million QSB gross income test can exchange their unused R&D credits at a rate of 90% of the credit’s value.15
• Purpose: This legislative change provides a significant boost to cash flow for these typically pre-profit companies, lowering the effective cost of R&D capital and enhancing investment in the state.15

The enhancement substantially improves the efficiency of credit monetization. To reach the $\$1.5$ million cap at the 90% rate, a biotech QSB only needs to generate $\$1,666,667$ of credit $(\$1,500,000 / 0.90)$. This requires generating over $\$640,000$ less in credit value compared to the standard 65% rate to achieve the same maximum cash refund. This targeted policy acts as a highly subsidized grant program for qualifying biotech firms.

V. DRS Guidance and Mandatory Compliance Procedures

The Connecticut Department of Revenue Services (DRS) governs the compliance procedures for the R&D credit exchange, requiring a formal application process and specific disclosures to ensure statutory eligibility.

A. Required Forms and Dedicated Filing Protocol

The application for exchange must be made using Form CT-1120 XCH, Application for Exchange of Research and Development or Research and Experimental Expenditures Tax Credits by a Qualified Small Business.6

The filing requires several documents to be submitted concurrently:

1. Form CT-1120 (or CT-1120CU): The corporate business tax return must indicate the election to exchange credits and include the requested refund amount.6
2. Form CT-1120RC or CT-1120 RDC: These forms are essential for calculating the amount of credit earned in the current year and determining the available balance for exchange.6
3. Form CT-1120 XCH: The application itself, which must be filed separately from the main tax return.6 This application must attach the R&D credit calculation forms and all required supporting schedules and documentation.6

The completed application and supporting information are not sent to the general DRS filing address but are directed specifically to the unit responsible for compliance verification:

Department of Revenue Services. Corporation Tax Audit Unit Attn: XCH. 450 Columbus Blvd Ste 1. Hartford CT 06103‑1837.6

The requirement to submit the application to the Corporation Tax Audit Unit confirms that the DRS treats the exchange request as an initial audit function, prioritizing the verification of the QSB status and the legitimacy of the claimed R&D expenditures before issuing a direct cash disbursement.

B. Verification of QSB Status on Form CT-1120 XCH

Form CT-1120 XCH requires specific line item responses that address both the quantitative and qualitative elements of the $\$70$ million test.12

Line 3 of Part I requires the applicant to Enter the total gross income of the company for the previous income year from all sources.12 This numerical entry is the direct calculation used by the DRS to confirm that the gross income does not exceed the $\$70$ million statutory maximum. If the income exceeds this amount, the company is ineligible, and the election box on Form CT-1120 must not be checked.12

Lines 2 and 3 of Part I of Form CT-1120 XCH enforce the related person anti-abuse rule.12 If the company engaged in transactions with related persons during the income year, the taxpayer must check “Yes” and provide substantial documentation, including 12:

• Identification of related persons, their gross incomes, and their relationship to the company.
• An organizational chart of the related group.
• A separate schedule detailing each transaction with related persons, the dates of these transactions, and the gross income derived by the applicant from each transaction.

This stringent documentation requirement compels taxpayers to prepare evidence substantiating that the QSB’s primary revenue streams are not artificially generated by transactions within a controlled group that would otherwise exceed the $\$70$ million threshold. This information allows the Audit Unit to perform the necessary substance-over-form analysis mandated by CGS § 12-217ee. Additionally, the form verifies that the company does not have any taxes due and unpaid to the State of Connecticut, including interest and penalties, as outstanding liabilities must be settled prior to receiving a refund.12

VI. Illustrative Case Studies: Navigating the $70$ Million Test

The following case studies illustrate how the $\$70$ million test and the related anti-abuse provisions apply in practice.

A. Case Study 1: Standard QSB Qualification and Cap Management

Scenario: Alpha Devices Corporation, a Connecticut C-Corp, develops advanced IoT sensors. Its Prior Year Gross Income was $\$45,000,000$. The company is currently operating at a net loss, resulting in $\$0$ CBT liability. Alpha Devices generated $\$2,500,000$ in Research and Experimental Expenditures (RC) credit this year. It has no related-person transactions.

Analysis and Outcome:

1. QSB Status: Alpha Devices meets the primary quantitative test as its gross income of $\$45$ million is below the $\$70$ million limit.9 It also has no liability, meeting the exchange prerequisite.3
2. Refund Rate: The standard 65% exchange rate applies.
3. Applying the Cap: While the company generated $\$2,500,000$ in credit, the maximum allowable refund is $\$1,500,000$.3
4. Credit Utilization: To reach the cap, the company must exchange $\$2,307,692$ of its credit $(\$1,500,000 / 0.65)$.
5. Conclusion: Alpha Devices Corporation receives a cash refund of $1,500,000. The remaining unused credit of $\$192,308$ $(\$2,500,000 – \$2,307,692)$ must be carried forward for up to 15 years.1

B. Case Study 2: Disqualification via Related Person Transactions

Scenario: Chem-R&D Services is a U.S. subsidiary (C-Corp) of Pharma Global, a multinational entity that operates worldwide. Chem-R&D Services’ standalone Prior Year Gross Income was $\$68,000,000$. Chem-R&D generated $\$800,000$ in RDC credit this year but has negative net income. Crucially, 95% of Chem-R&D’s gross income is derived from R&D contracts performed exclusively for Pharma Global affiliates.

Analysis and Outcome:

1. Numerical Compliance: Numerically, the $\$68$ million gross income is below the $\$70$ million limit.
2. Related Person Scrutiny: Chem-R&D is controlled by Pharma Global (meeting the CGS § 12-217w control standard).14 Given that nearly all its gross income is derived from transactions with related persons, the DRS Audit Unit will scrutinize the application closely upon review of the CT-1120 XCH disclosures.12
3. DRS Determination: The Commissioner is highly likely to determine that Chem-R&D met the gross income test through these related-party transactions, effectively operating as a segregated R&D unit for a much larger group that would not qualify under the $\$70$ million test. The intent of the anti-abuse rule is to disallow such structural arrangements.
4. Conclusion: The exchange application is denied under CGS § 12-217ee(e)(2). Chem-R&D Services cannot monetize the credit but retains the full $\$800,000$ R&D credit for indefinite carryforward.1

C. Case Study 3: Maximizing the Enhanced Biotech Rate (Post-2025)

Scenario: BioGen Therapeutics, a qualifying small biotech C-corporation, files its 2026 return. Its Prior Year Gross Income (2025) was $\$55,000,000$. BioGen generated $\$1,000,000$ in R&D credits and has negative apportioned net income.

Analysis and Outcome:

1. QSB Status and Rate: BioGen meets the $\$70$ million QSB test and qualifies for the enhanced biotech rate of 90% (effective for income years beginning on or after January 1, 2025).15
2. Refund Calculation: BioGen exchanges the full $\$1,000,000$ credit, as this amount is far below the cap.
3. Refund Amount: $\$1,000,000 \times 90\% = \$900,000$.
4. Strategic Advantage: The utilization of the 90% rate yields a cash refund of $\$900,000$. If the company had filed this claim in the 2024 tax year, the same $\$1$ million credit would only have produced a $\$650,000$ refund $(\$1,000,000 \times 65\%)$. The enhanced rate represents a $\$250,000$ increase in immediate working capital, demonstrating the powerful cash flow incentive the state offers to the biotechnology industry.

VII. Conclusion and Strategic Tax Planning Recommendations

The Connecticut Corporate Gross Income Test (CGS § 12-217ee) is a central component of the state’s R&D tax credit exchange program, designed to channel critical research funding into genuine Qualified Small Businesses. The law is distinguished by its dual thresholds—a $\$100$ million limit for calculation benefit and a $\$70$ million limit for cash exchange—reflecting a deliberate effort by the state to impose stricter controls on direct cash disbursements.

A. Compliance and Risk Mitigation

The most significant risk to QSB eligibility lies not in failing the numerical $\$70$ million test, but in failing the substantive scrutiny imposed by the Related Person Anti-Abuse Provision (CGS § 12-217w).9 By directing exchange applications to the Corporation Tax Audit Unit and requiring mandatory disclosures of intercompany transactions on Form CT-1120 XCH, the DRS has established a clear administrative mechanism for identifying and disallowing structural arrangements designed solely to meet the income threshold.6 For companies within affiliated groups, proving economic independence and sound business purpose for all related-party revenues is paramount.

B. Strategic Optimization and Future Planning

1. Prior-Year Gross Income Monitoring: Corporations that historically operate between $\$60$ million and $\$75$ million in gross income must meticulously project and monitor their prior-year income figures to confirm QSB eligibility for the refund program. The $\$70$ million limit is a hard cap; exceeding it by even a small margin necessitates carrying forward all unused credits rather than monetizing them.
2. Maximizing the Refund Cap: Taxpayers must continually analyze the trade-off between receiving immediate cash (at 65% or 90% value, up to the $\$1.5$ million cap) versus carrying forward 100% of the credit value.3 For high-expenditure firms, generating credit beyond the amount required to maximize the cash refund $(\$2,307,692$ at 65%; $\$1,666,667$ at 90%) should be managed strategically, ensuring the excess credit is carried forward rather than surrendered unnecessarily.
3. Biotechnology Sector Planning: Qualifying small biotech C-corporations should recognize the substantial advantage conferred by the 90% exchange rate, effective January 1, 2025. This increase significantly enhances cash flow and should factor heavily into capital allocation and R&D expenditure planning, reducing the effective financing cost of research activities performed in Connecticut.16

R&D Tax Credit Preparation Services

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.

If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services

creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees

Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/